Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
Korean Journal of Hematology
;
: 102-108, 2010.
Article
in English
| WPRIM
| ID: wpr-720273
ABSTRACT
BACKGROUND:
A combination of busulfan (Bu) and cyclophosphamide (Cy) has been used as a standard myeloablative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). Recent studies postulate that fludarabine (Flu) is a less toxic substitute for Cy.METHODS:
Forty-two patients who were diagnosed with acute leukemia or myelodysplastic syndrome and received BuFlu (n=17) or BuCy (n=25) from August, 1999 to July, 2009 at Dong-A University Medical Center were retrospectively analyzed.RESULTS:
The median follow-up duration was 39.75 months. The BuFlu group showed a lower incidence of mucositis (P=0.005), but there was no significant intergroup difference in the time of engraftment, nausea/vomiting, acute/chronic graft-versus-host disease, hepatic veno-occlusive disease, or hemorrhagic cystitis. Moreover, the 2 groups showed no significant difference in the cumulative risk of relapse, event-free survival, or overall survival.CONCLUSION:
BuFlu administration can be employed as a preparative regimen for allogeneic HSCT and shows efficacy and transplant-adverse effects comparable to those of BuCy. However, randomized prospective studies in more patients are warranted.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Vidarabine
/
Behavior Therapy
/
Myelodysplastic Syndromes
/
Hepatic Veno-Occlusive Disease
/
Busulfan
/
Leukemia
/
Incidence
/
Retrospective Studies
/
Follow-Up Studies
Type of study:
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Humans
Language:
English
Journal:
Korean Journal of Hematology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS